Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Metastatic Castration-resistant Prostate Cancer × ebastine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1

Interventions

Prednisone 2 Pluvicto 2 sarilumab 1 rucaparib 1 ebastine 1 copanlisib 1 cemiplimab 1 cabazitaxel 1 afuresertib 1 Docetaxel 1 Clinical Trials, Phase I as Topic 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06480110 2025-04-13

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Rigshospitalet, Denmark

Phase 1/2 Recruiting

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡